Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and traztuzumab (H) (TCH): A phase II trial

First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and traztuzumab (H) (TCH): A phase II trial. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2003.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.